Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
Identifieur interne : 00A250 ( Main/Exploration ); précédent : 00A249; suivant : 00A251Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
Auteurs : John Mcmurray [Royaume-Uni] ; Alain Cohen-Solal [France] ; Rainer Dietz [Allemagne] ; Eric Eichhorn [États-Unis] ; Leif Erhardt [Suède] ; F. D. Richard Hobbs [Royaume-Uni] ; Henry Krum [Australie] ; Aldo Maggioni [Italie] ; Robert S. Mckelvie [Canada] ; Ileana L. Pi A [États-Unis] ; Jordi Soler-Soler [Espagne] ; Karl Swedberg [Suède]Source :
- European Journal of Heart Failure [ 1388-9842 ] ; 2005-08.
English descriptors
- KwdEn :
- Aetiology, Aldosterone, Aldosterone antagonist, Aldosterone antagonists, Angiotensin, Angiotensin receptor blockers, Angiotensinconverting enzyme inhibitors, Antagonist, Arb, Arch intern, Asymptomatic, Beta, Beta blocker, Beta blockers, Biochemical monitoring, Blocker, Blood chemistry, Blood pressure, Calcium channel blockers, Candesartan, Cardiol, Cardiology, Carvedilol, Check blood chemistry, Chronic heart failure, Clinical practice, Clinical recommendations, Clinical trials, Coll cardiol, Combination preparations, Congestive, Congestive heart failure, Creatinine, Daily target dose, Digoxin, Diuretic, Diuretic dose, Diuretics amiloride, Dos, Dose, Dose advice, Double dose, Drug interactions, Dysfunction, Elderly patients, Engl, Enzyme inhibitors, Eplerenone, European journal, European society, Final dose titration, General practitioners, Guideline, Heart failure, Heart failure patients, Heart rate, Hospital admission, Hospital admissions, Hyperkalaemia, Hypotension, Increase survival, Inhibitor, Isosorbide dinitrate, Line treatment, Mcmurray, Metoprolol, Morbidity, Nsaid, Nyha, Nyha class, Other vasodilators, Patient education, Practical guidance, Practical recommendations, Practice guidelines, Primary care, Randomised, Randomised trial, Randomized, Randomized trial, Receptor, Renal, Renal dysfunction, Renal function, Renin angiotensin aldosterone system, Salt substitutes, Significant hyperkalaemia, Specialist advice, Spironolactone, Standard therapy, Systolic, Systolic dysfunction, Target dose, Treatment discontinuation, Valsartan, Ventricular, Ventricular dysfunction, Ventricular systolic dysfunction, Weekly intervals.
- Teeft :
- Aetiology, Aldosterone, Aldosterone antagonist, Aldosterone antagonists, Angiotensin, Angiotensin receptor blockers, Angiotensinconverting enzyme inhibitors, Antagonist, Arb, Arch intern, Asymptomatic, Beta, Beta blocker, Beta blockers, Biochemical monitoring, Blocker, Blood chemistry, Blood pressure, Calcium channel blockers, Candesartan, Cardiol, Cardiology, Carvedilol, Check blood chemistry, Chronic heart failure, Clinical practice, Clinical recommendations, Clinical trials, Coll cardiol, Combination preparations, Congestive, Congestive heart failure, Creatinine, Daily target dose, Digoxin, Diuretic, Diuretic dose, Diuretics amiloride, Dos, Dose, Dose advice, Double dose, Drug interactions, Dysfunction, Elderly patients, Engl, Enzyme inhibitors, Eplerenone, European journal, European society, Final dose titration, General practitioners, Guideline, Heart failure, Heart failure patients, Heart rate, Hospital admission, Hospital admissions, Hyperkalaemia, Hypotension, Increase survival, Inhibitor, Isosorbide dinitrate, Line treatment, Mcmurray, Metoprolol, Morbidity, Nsaid, Nyha, Nyha class, Other vasodilators, Patient education, Practical guidance, Practical recommendations, Practice guidelines, Primary care, Randomised, Randomised trial, Randomized, Randomized trial, Receptor, Renal, Renal dysfunction, Renal function, Renin angiotensin aldosterone system, Salt substitutes, Significant hyperkalaemia, Specialist advice, Spironolactone, Standard therapy, Systolic, Systolic dysfunction, Target dose, Treatment discontinuation, Valsartan, Ventricular, Ventricular dysfunction, Ventricular systolic dysfunction, Weekly intervals.
Abstract
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well‐being and prolong life. This may be due to unfamiliarity with the evidence‐base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta‐blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non‐specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.
Url:
DOI: 10.1016/j.ejheart.2005.07.002
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Italie, Royaume-Uni, Suède, États-Unis
- Angleterre, Berlin, Catalogne, Midlands de l'Ouest, Ontario, Texas, Victoria (État)
- Barcelone, Berlin, Birmingham, Dallas, Hamilton (Ontario), Melbourne
- Université McMaster
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000444
- to stream Istex, to step Curation: 000444
- to stream Istex, to step Checkpoint: 001807
- to stream Main, to step Merge: 00AE15
- to stream Main, to step Curation: 00A250
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice</title><author><name sortKey="Mcmurray, John" sort="Mcmurray, John" uniqKey="Mcmurray J" first="John" last="Mcmurray">John Mcmurray</name></author><author><name sortKey="Cohen Olal, Alain" sort="Cohen Olal, Alain" uniqKey="Cohen Olal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name></author><author><name sortKey="Dietz, Rainer" sort="Dietz, Rainer" uniqKey="Dietz R" first="Rainer" last="Dietz">Rainer Dietz</name></author><author><name sortKey="Eichhorn, Eric" sort="Eichhorn, Eric" uniqKey="Eichhorn E" first="Eric" last="Eichhorn">Eric Eichhorn</name></author><author><name sortKey="Erhardt, Leif" sort="Erhardt, Leif" uniqKey="Erhardt L" first="Leif" last="Erhardt">Leif Erhardt</name></author><author><name sortKey="Hobbs, F D Richard" sort="Hobbs, F D Richard" uniqKey="Hobbs F" first="F. D. Richard" last="Hobbs">F. D. Richard Hobbs</name></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></author><author><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name></author><author><name sortKey="Mckelvie, Robert S" sort="Mckelvie, Robert S" uniqKey="Mckelvie R" first="Robert S." last="Mckelvie">Robert S. Mckelvie</name></author><author><name sortKey="Pi A, Ileana L" sort="Pi A, Ileana L" uniqKey="Pi A I" first="Ileana L." last="Pi A">Ileana L. Pi A</name></author><author><name sortKey="Soler Oler, Jordi" sort="Soler Oler, Jordi" uniqKey="Soler Oler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:172643E06E2B85545E1B8E28500B065F105F8F4C</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1016/j.ejheart.2005.07.002</idno><idno type="url">https://api.istex.fr/document/172643E06E2B85545E1B8E28500B065F105F8F4C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000444</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000444</idno><idno type="wicri:Area/Istex/Curation">000444</idno><idno type="wicri:Area/Istex/Checkpoint">001807</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001807</idno><idno type="wicri:doubleKey">1388-9842:2005:Mcmurray J:practical:recommendations:for</idno><idno type="wicri:Area/Main/Merge">00AE15</idno><idno type="wicri:Area/Main/Curation">00A250</idno><idno type="wicri:Area/Main/Exploration">00A250</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice</title><author><name sortKey="Mcmurray, John" sort="Mcmurray, John" uniqKey="Mcmurray J" first="John" last="Mcmurray">John Mcmurray</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Cardiology, Western Infirmary, G12 8QQ, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Cohen Olal, Alain" sort="Cohen Olal, Alain" uniqKey="Cohen Olal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hopital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Dietz, Rainer" sort="Dietz, Rainer" uniqKey="Dietz R" first="Rainer" last="Dietz">Rainer Dietz</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Franz‐Volhard‐Klinik, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Eichhorn, Eric" sort="Eichhorn, Eric" uniqKey="Eichhorn E" first="Eric" last="Eichhorn">Eric Eichhorn</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>VA Hospital, Dallas</wicri:regionArea><placeName><settlement type="city">Dallas</settlement><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Erhardt, Leif" sort="Erhardt, Leif" uniqKey="Erhardt L" first="Leif" last="Erhardt">Leif Erhardt</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>University Hospital, Malmo</wicri:regionArea><wicri:noRegion>Malmo</wicri:noRegion></affiliation></author><author><name sortKey="Hobbs, F D Richard" sort="Hobbs, F D Richard" uniqKey="Hobbs F" first="F. D. Richard" last="Hobbs">F. D. Richard Hobbs</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Primary Care and General Practice, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Departments of Epidemiology and Preventive Medicine and Medicine, Monash University/Alfred Hospital, Victoria, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Research Centre, ANMCO, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author><author><name sortKey="Mckelvie, Robert S" sort="Mckelvie, Robert S" uniqKey="Mckelvie R" first="Robert S." last="Mckelvie">Robert S. Mckelvie</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, McMaster University, Hamilton</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Pi A, Ileana L" sort="Pi A, Ileana L" uniqKey="Pi A I" first="Ileana L." last="Pi A">Ileana L. Pi A</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Case Western Reserve University, Ohio, Cleveland</wicri:regionArea><wicri:noRegion>Cleveland</wicri:noRegion></affiliation></author><author><name sortKey="Soler Oler, Jordi" sort="Soler Oler, Jordi" uniqKey="Soler Oler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>University General Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Medicine, Sahlgrenska University Hospital/Östra, Sahlgrenska Academy at Göteborg University, Gothenburg</wicri:regionArea><wicri:noRegion>Gothenburg</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">European Journal of Heart Failure</title><title level="j" type="alt">EUROPEAN JOURNAL OF HEART FAILURE</title><idno type="ISSN">1388-9842</idno><idno type="eISSN">1879-0844</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="710">710</biblScope><biblScope unit="page" to="721">721</biblScope><biblScope unit="page-count">12</biblScope><date type="published" when="2005-08">2005-08</date></imprint><idno type="ISSN">1388-9842</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1388-9842</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aetiology</term><term>Aldosterone</term><term>Aldosterone antagonist</term><term>Aldosterone antagonists</term><term>Angiotensin</term><term>Angiotensin receptor blockers</term><term>Angiotensinconverting enzyme inhibitors</term><term>Antagonist</term><term>Arb</term><term>Arch intern</term><term>Asymptomatic</term><term>Beta</term><term>Beta blocker</term><term>Beta blockers</term><term>Biochemical monitoring</term><term>Blocker</term><term>Blood chemistry</term><term>Blood pressure</term><term>Calcium channel blockers</term><term>Candesartan</term><term>Cardiol</term><term>Cardiology</term><term>Carvedilol</term><term>Check blood chemistry</term><term>Chronic heart failure</term><term>Clinical practice</term><term>Clinical recommendations</term><term>Clinical trials</term><term>Coll cardiol</term><term>Combination preparations</term><term>Congestive</term><term>Congestive heart failure</term><term>Creatinine</term><term>Daily target dose</term><term>Digoxin</term><term>Diuretic</term><term>Diuretic dose</term><term>Diuretics amiloride</term><term>Dos</term><term>Dose</term><term>Dose advice</term><term>Double dose</term><term>Drug interactions</term><term>Dysfunction</term><term>Elderly patients</term><term>Engl</term><term>Enzyme inhibitors</term><term>Eplerenone</term><term>European journal</term><term>European society</term><term>Final dose titration</term><term>General practitioners</term><term>Guideline</term><term>Heart failure</term><term>Heart failure patients</term><term>Heart rate</term><term>Hospital admission</term><term>Hospital admissions</term><term>Hyperkalaemia</term><term>Hypotension</term><term>Increase survival</term><term>Inhibitor</term><term>Isosorbide dinitrate</term><term>Line treatment</term><term>Mcmurray</term><term>Metoprolol</term><term>Morbidity</term><term>Nsaid</term><term>Nyha</term><term>Nyha class</term><term>Other vasodilators</term><term>Patient education</term><term>Practical guidance</term><term>Practical recommendations</term><term>Practice guidelines</term><term>Primary care</term><term>Randomised</term><term>Randomised trial</term><term>Randomized</term><term>Randomized trial</term><term>Receptor</term><term>Renal</term><term>Renal dysfunction</term><term>Renal function</term><term>Renin angiotensin aldosterone system</term><term>Salt substitutes</term><term>Significant hyperkalaemia</term><term>Specialist advice</term><term>Spironolactone</term><term>Standard therapy</term><term>Systolic</term><term>Systolic dysfunction</term><term>Target dose</term><term>Treatment discontinuation</term><term>Valsartan</term><term>Ventricular</term><term>Ventricular dysfunction</term><term>Ventricular systolic dysfunction</term><term>Weekly intervals</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Aetiology</term><term>Aldosterone</term><term>Aldosterone antagonist</term><term>Aldosterone antagonists</term><term>Angiotensin</term><term>Angiotensin receptor blockers</term><term>Angiotensinconverting enzyme inhibitors</term><term>Antagonist</term><term>Arb</term><term>Arch intern</term><term>Asymptomatic</term><term>Beta</term><term>Beta blocker</term><term>Beta blockers</term><term>Biochemical monitoring</term><term>Blocker</term><term>Blood chemistry</term><term>Blood pressure</term><term>Calcium channel blockers</term><term>Candesartan</term><term>Cardiol</term><term>Cardiology</term><term>Carvedilol</term><term>Check blood chemistry</term><term>Chronic heart failure</term><term>Clinical practice</term><term>Clinical recommendations</term><term>Clinical trials</term><term>Coll cardiol</term><term>Combination preparations</term><term>Congestive</term><term>Congestive heart failure</term><term>Creatinine</term><term>Daily target dose</term><term>Digoxin</term><term>Diuretic</term><term>Diuretic dose</term><term>Diuretics amiloride</term><term>Dos</term><term>Dose</term><term>Dose advice</term><term>Double dose</term><term>Drug interactions</term><term>Dysfunction</term><term>Elderly patients</term><term>Engl</term><term>Enzyme inhibitors</term><term>Eplerenone</term><term>European journal</term><term>European society</term><term>Final dose titration</term><term>General practitioners</term><term>Guideline</term><term>Heart failure</term><term>Heart failure patients</term><term>Heart rate</term><term>Hospital admission</term><term>Hospital admissions</term><term>Hyperkalaemia</term><term>Hypotension</term><term>Increase survival</term><term>Inhibitor</term><term>Isosorbide dinitrate</term><term>Line treatment</term><term>Mcmurray</term><term>Metoprolol</term><term>Morbidity</term><term>Nsaid</term><term>Nyha</term><term>Nyha class</term><term>Other vasodilators</term><term>Patient education</term><term>Practical guidance</term><term>Practical recommendations</term><term>Practice guidelines</term><term>Primary care</term><term>Randomised</term><term>Randomised trial</term><term>Randomized</term><term>Randomized trial</term><term>Receptor</term><term>Renal</term><term>Renal dysfunction</term><term>Renal function</term><term>Renin angiotensin aldosterone system</term><term>Salt substitutes</term><term>Significant hyperkalaemia</term><term>Specialist advice</term><term>Spironolactone</term><term>Standard therapy</term><term>Systolic</term><term>Systolic dysfunction</term><term>Target dose</term><term>Treatment discontinuation</term><term>Valsartan</term><term>Ventricular</term><term>Ventricular dysfunction</term><term>Ventricular systolic dysfunction</term><term>Weekly intervals</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well‐being and prolong life. This may be due to unfamiliarity with the evidence‐base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta‐blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non‐specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Berlin</li><li>Catalogne</li><li>Midlands de l'Ouest</li><li>Ontario</li><li>Texas</li><li>Victoria (État)</li></region><settlement><li>Barcelone</li><li>Berlin</li><li>Birmingham</li><li>Dallas</li><li>Hamilton (Ontario)</li><li>Melbourne</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Mcmurray, John" sort="Mcmurray, John" uniqKey="Mcmurray J" first="John" last="Mcmurray">John Mcmurray</name></noRegion><name sortKey="Hobbs, F D Richard" sort="Hobbs, F D Richard" uniqKey="Hobbs F" first="F. D. Richard" last="Hobbs">F. D. Richard Hobbs</name><name sortKey="Mcmurray, John" sort="Mcmurray, John" uniqKey="Mcmurray J" first="John" last="Mcmurray">John Mcmurray</name></country><country name="France"><noRegion><name sortKey="Cohen Olal, Alain" sort="Cohen Olal, Alain" uniqKey="Cohen Olal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Dietz, Rainer" sort="Dietz, Rainer" uniqKey="Dietz R" first="Rainer" last="Dietz">Rainer Dietz</name></region></country><country name="États-Unis"><region name="Texas"><name sortKey="Eichhorn, Eric" sort="Eichhorn, Eric" uniqKey="Eichhorn E" first="Eric" last="Eichhorn">Eric Eichhorn</name></region><name sortKey="Pi A, Ileana L" sort="Pi A, Ileana L" uniqKey="Pi A I" first="Ileana L." last="Pi A">Ileana L. Pi A</name></country><country name="Suède"><noRegion><name sortKey="Erhardt, Leif" sort="Erhardt, Leif" uniqKey="Erhardt L" first="Leif" last="Erhardt">Leif Erhardt</name></noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></region></country><country name="Italie"><noRegion><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name></noRegion></country><country name="Canada"><region name="Ontario"><name sortKey="Mckelvie, Robert S" sort="Mckelvie, Robert S" uniqKey="Mckelvie R" first="Robert S." last="Mckelvie">Robert S. Mckelvie</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Soler Oler, Jordi" sort="Soler Oler, Jordi" uniqKey="Soler Oler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A250 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A250 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:172643E06E2B85545E1B8E28500B065F105F8F4C
|texte= Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
}}
| This area was generated with Dilib version V0.6.33. |  |